title: Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor.
abstract: Although metastasis accounts for >90% of cancer-related deaths, no therapeutic that targets this process has yet been approved. Because the chemokine receptor CXCR4 is one of the targets closely linked with tumor metastasis, inhibitors of this receptor have the potential to abrogate metastasis. In the current report, we demonstrate that celastrol can downregulate the CXCR4 expression on breast cancer MCF-7 cells stably transfected with HER2, an oncogene known to induce the chemokine receptor. Downregulation of CXCR4 by the triterpenoid was not cell type-specific as downregulation occurred in colon cancer, squamous cell carcinoma, and pancreatic cancer cells. Decrease in CXCR4 expression was not due to proteolysis as neither proteasome inhibitors nor lysosomal stabilization had any effect. Quantitative reverse transcription polymerase chain reaction analysis revealed that downregulation of CXCR4 messenger RNA (mRNA) by celastrol occurred at the translational level. Chromatin immunoprecipitation analysis revealed regulation at the transcriptional level as well. Abrogation of the chemokine receptor by celastrol or by gene-silencing was accompanied by suppression of invasiveness of colon cancer cells induced by CXCL12, the ligand for CXCR4. This effect was not cell type-specific as celastrol also abolished invasiveness of pancreatic tumor cells, and this effect again correlated with the disappearance of both the CXCR4 mRNA and CXCR4 protein. Other triterpenes, such as withaferin A and gedunin, which are known to inhibit Hsp90, did not downregulate CXCR4 expression, indicating that the effects were specific to celastrol. Overall, these results show that celastrol has potential in suppressing invasion and metastasis of cancer cells by down-modulation of CXCR4 expression.
authors.affiliation: Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
authors.forename: Vivek R
authors.initials: VR
authors.lastname: Yadav
authors.forename: Bokyung
authors.initials: B
authors.lastname: Sung
authors.forename: Sahdeo
authors.initials: S
authors.lastname: Prasad
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Kannappan
authors.forename: Sung-Gook
authors.initials: SG
authors.lastname: Cho
authors.forename: Mingyao
authors.initials: M
authors.lastname: Liu
authors.forename: Madan M
authors.initials: MM
authors.lastname: Chaturvedi
authors.forename: Bharat B
authors.initials: BB
authors.lastname: Aggarwal
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000235:genetics / Q000473:pathology*; D015536:Down-Regulation / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009928:Organ Specificity / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000473:pathology*; D053978:Pentacyclic Triterpenes; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000235:genetics* / Q000378:metabolism; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D018841:HSP90 Heat-Shock Proteins; D016328:NF-kappa B; D053978:Pentacyclic Triterpenes; D019718:Receptors, CXCR4; D014315:Triterpenes; D014409:Tumor Necrosis Factor-alpha; C050414:celastrol
references.citation: Angew Chem Int Ed Engl. 2009;48(32):5853-5
references.pmid: 19585625
references.citation: Cancer Res. 2002 Dec 15;62(24):7203-6
references.pmid: 12499259
references.citation: Clin Exp Metastasis. 2005;22(1):39-46
references.pmid: 16132577
references.citation: Cancer Res. 2009 Oct 15;69(20):7905-10
references.pmid: 19826039
references.citation: J Biol Chem. 2009 Dec 18;284(51):35381-9
references.pmid: 19858214
references.citation: Cell Stem Cell. 2008 Apr 10;2(4):333-44
references.pmid: 18397753
references.citation: Cancer Res. 2002 Mar 15;62(6):1832-7
references.pmid: 11912162
references.citation: Cancer Res. 2003 Jul 1;63(13):3833-9
references.pmid: 12839981
references.citation: Ann Surg Oncol. 2009 Sep;16(9):2645-53
references.pmid: 19588204
references.citation: Planta Med. 2004 Feb;70(2):93-103
references.pmid: 14994184
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Blood. 2007 Apr 1;109(7):2727-35
references.pmid: 17110449
references.citation: J Biol Chem. 2003 Jun 13;278(24):21631-8
references.pmid: 12690099
references.citation: J Exp Med. 1993 May 1;177(5):1391-8
references.pmid: 8478614
references.citation: J Biol Chem. 2007 Dec 21;282(51):36971-9
references.pmid: 17947233
references.citation: Dev Cell. 2003 Nov;5(5):709-22
references.pmid: 14602072
references.citation: Cancer Res. 2010 Mar 1;70(5):1951-9
references.pmid: 20160026
references.citation: Cancer Res. 2004 Nov 15;64(22):8420-7
references.pmid: 15548713
references.citation: Cancer Res. 2005 Nov 1;65(21):9891-8
references.pmid: 16267013
references.citation: Biochem Pharmacol. 2006 Nov 15;72(10):1311-21
references.pmid: 16984800
references.citation: Cancer Res. 2006 May 1;66(9):4758-65
references.pmid: 16651429
references.citation: Cancer Cell. 2004 Nov;6(5):459-69
references.pmid: 15542430
references.citation: Cell. 2008 Sep 5;134(5):769-81
references.pmid: 18775310
references.citation: J Biol Chem. 2010 Feb 5;285(6):4224-4231
references.pmid: 19996313
references.citation: Blood. 2008 Jun 15;111(12):5654-62
references.pmid: 18305216
references.citation: J Leukoc Biol. 2006 Aug;80(2):309-19
references.pmid: 16769766
references.citation: Cancer Cell. 2009 Mar 3;15(3):220-31
references.pmid: 19249680
references.citation: Int J Cancer. 2007 Nov 15;121(10):2119-24
references.pmid: 17849476
references.citation: J Surg Res. 2007 Jul;141(1):53-9
references.pmid: 17574038
references.citation: J Biol Chem. 2004 Dec 31;279(53):56053-60
references.pmid: 15509580
references.citation: Cancer Cell. 2006 Oct;10(4):321-30
references.pmid: 17010675
references.citation: Cancer Res. 2005 Nov 15;65(22):10355-62
references.pmid: 16288025
references.citation: J Cell Physiol. 2006 Dec;209(3):645-52
references.pmid: 17001676
references.citation: Carcinogenesis. 2007 Feb;28(2):267-79
references.pmid: 16840440
references.citation: Biosci Biotechnol Biochem. 2003 Sep;67(9):1883-7
references.pmid: 14519971
references.citation: Nature. 2001 Mar 1;410(6824):50-6
references.pmid: 11242036
references.citation: Bioorg Med Chem Lett. 1998 Dec 15;8(24):3659-64
references.pmid: 9934491
references.citation: Biochem Biophys Res Commun. 2010 Apr 9;394(3):439-42
references.pmid: 20226165
references.citation: Ann N Y Acad Sci. 2004 Dec;1030:162-9
references.pmid: 15659794
references.citation: J Biol Chem. 2001 Dec 7;276(49):45509-12
references.pmid: 11641392
references.citation: Mol Cell. 2003 Dec;12(6):1577-89
references.pmid: 14690609
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2339-47
references.pmid: 19671767